Investigation of the ALLEGRA THV System With a New Delivery System in Patients With Aortic Stenosis or Failed Surgical Bioprosthesis
This trial has no sites in United States.
It has sites in 3 countries. Choose a country to see its sites.
Trial details
- Who runs it
- NVT GmbH
- Trial code
- NCT05478161
- Record updated
- 24 February 2026
- Original description
The EMPIRE study confirms the technical performance of the new IMPERIA Delivery System and evaluates the safety and efficacy of the entire ALLEGRA THV System.Read full original descriptionShow less
Investigation of the Safety and Performance of the NVT ALLEGRA THV System With a New Delivery System in Patients With Severe Calcified Aortic Stenosis or Failed Surgical Aortic Bioprosthesis
The EMPIRE study confirms the technical performance of the new IMPERIA Delivery System and evaluates the safety and efficacy of the entire ALLEGRA THV System.
The primary endpoint is device success rate at 7 days (discharge from index procedure or 7 days post implant, whichever comes first), as defined by VARC 2.
Based on the outcomes of a study with a similar device and considering a drop-out rate of 5%, 107 patients need to be enrolled in the study.
Inclusion: Symptomatic severe calcific stenosis of a native aortic valve with an AVA ≤1.0 cm2 (or AVA index ≤0.6 cm2/m2), AND mean aortic pressure gradient ≥ 40mmHg OR maximal transaortic velocity ≥4.0m/s OR Doppler velocity index ≤0.25 on site-reported echocardiography OR symptomatic patients with degeneration of a surgical bioprosthetic valve (stenosis +/- insufficiency) on site-reported echocardiography; Local multi-disciplinary Heart Team and Central Screening Committee (CSC) agree on indication and eligibility for TAVI; Age ≥18 years; Patient has signed the Patient Informed Consent Form; Patient is willing and able to comply with requirements of the study, including all follow-up visits.
Exclusion: Any percutaneous interventional procedure (e.g. PCI with stenting) within 14 days prior of the index procedure; Acute MI ≤30 days prior to the index procedure; Cerebrovascular accident (CVA) or transient ischemic attack (TIA) ≤6 months or prior CVA with moderate or severe disability (e.g. modified Rankin scale score >2); Required emergency surgery for any reason; Currently participating in another investigational drug or device study; Distance between native aortic valve basal plane and the orifice of the lowest coronary artery <8 mm; Specific exclusions in patients with degenerated surgical bioprosthetic aortic valves (valve-in-valve) (site-reported):; Significant disease of the aorta that would preclude safe advancement of the ALLEGRA THV System; Severe ilio-femoral vessel disease that would preclude safe placement of an 18 Fr introducer sheath or make endovascular access impossible; Evidence of active endocarditis or other acute infections; Renal failure requiring continuous renal replacement therapy; Untreated clinically significant coronary artery disease requiring revascularization; Symptomatic carotid or vertebral artery disease requiring intervention or carotid/vertebral intervention within the preceding 45 days; Active peptic ulcer or gastrointestinal (GI) bleeding ≤3 months; Severe (greater than 3+) mitral insufficiency (site-reported); Life expectancy ≤12 months due to other medical illness; Pregnancy or intend to become pregnant during study participation; Specific exclusions in patients with native aortic valve disease (site-reported):; Severe left ventricular dysfunction with ejection fraction (EF) <20% (site-reported); History of bleeding diathesis or coagulopathy; acute blood dyscrasias as defined: thrombocytopenia (platelets <80,000/µl), acute anemia (hemoglobin <10 g/dl), leukopenia (WBC <3000/ µl); Known hypersensitivity to contrast media, which cannot be adequately pre-medicated or contraindication to anticoagulant or anti-platelet medication or to nitinol alloy or to bovine tissue; General:; Mean aortic annulus diameter as measured by pre-procedural CT or internal diameter of the bioprosthesis is <16.5 mm or >27 mm; Echocardiographic evidence of intracardiac thrombus or vegetation (site-reported); Porcelain aorta; Uncontrolled atrial fibrillation; Unicuspid or bicuspid aortic valve; Non-calcified aortic stenosis; Predominant aortic regurgitation > grade 3; Low position of the coronary ostia, especially in combination with shallow sinuses (high risk of coronary occlusion); Partially detached leaflets that may obstruct a coronary ostium.